Secondary efficacy outcomes
At 3 months from the axi-cel infusion, the investigator-assessed ORR was 75.8% (95% CI, 63.3–85.8%). In total, 37 patients (59.7%) remained in CMR, as assessed by the investigator, at 6 months from the axi-cel infusion (95% CI, 46.5–72.0%) (Extended Data Fig. At a median follow-up of 12.0 months, the median EFS from leukapheresis was 12.3 months (95% CI, 7.2–not reached; Fig. 